文章：

高危II期黑色素瘤的辅助治疗：当前管理范式与未来方向

Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions

原文发布日期：29 July 2024

DOI: 10.3390/cancers16152690

类型: Article

开放获取: 是

英文摘要：

Melanoma is the fifth most common cancer in the United States and accounts for the majority of all skin cancer-related deaths, making it the most lethal cutaneous malignancy. Systemic adjuvant therapy for stage IIB-IV melanoma is now approved for patients who have undergone surgical resection, given the appreciable risk of recurrence and mortality in this patient population. Despite the lower stage, high-risk stage II melanoma (stage IIB/IIC) can often exhibit an even more aggressive course when compared to stage IIIA/IIIB disease, thus justifying consideration of adjuvant therapy in these patients. In this review, we highlight the current standard of practice for the treatment of stage IIB/C melanoma, with a focus on adjuvant therapies supported by published landmark clinical trials, including anti-PD-1 therapy. Notably, adjuvant therapies approved thus far in this patient population have demonstrated an improvement in recurrence-free survival, while their impact on overall survival is pending. Finally, this review highlights currently ongoing trials and future directions for research and treatment possibilities for high-risk clinical stage II melanoma.

摘要翻译： 

黑色素瘤是美国第五大常见癌症，占所有皮肤癌相关死亡病例的绝大多数，是最致命的皮肤恶性肿瘤。鉴于IIB-IV期黑色素瘤患者存在显著的复发和死亡风险，目前对已完成手术切除的该分期患者已批准采用全身辅助治疗。尽管分期较低，但高危II期黑色素瘤（IIB/IIC期）相较于IIIA/IIIB期疾病往往表现出更具侵袭性的病程，因此有必要考虑对该类患者进行辅助治疗。本综述重点阐述当前IIB/C期黑色素瘤的治疗实践标准，聚焦于已发表里程碑式临床试验支持的辅助疗法，包括抗PD-1疗法。值得注意的是，目前该患者群体中获批的辅助疗法已证实可改善无复发生存期，但其对总生存期的影响尚待验证。最后，本文还重点介绍了当前正在进行的高危临床II期黑色素瘤相关试验，以及未来研究方向与治疗可能性。

原文链接：

Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions